Skip Navigation



Journal of the National Cancer Institute Advance Access published online on March 10, 2009
JNCI Journal of the National Cancer Institute, doi:10.1093/jnci/djp028
This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow All Versions of this Article:
101/6/362    most recent
djp028v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Request Permissions
Google Scholar
Right arrow Articles by Barry, M. J.
Right arrow Articles by Mulley, A. J.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Barry, M. J.
Right arrow Articles by Mulley, A. J., Jr
Related Collections
Right arrowRelated Articles in JNCI
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2009. Published by Oxford University Press.

EDITORIALS

Why Are a High Overdiagnosis Probability and a Long Lead Time for Prostate Cancer Screening So Important?

Michael J. Barry, Albert J. Mulley, Jr

Affiliations of authors: Medical Practices Evaluation Center, Massachusetts General Hospital, Boston, MA; Department of Medicine, Harvard Medical School, Boston, MA

Correspondence to: Michael J. Barry, MD, Medical Practices Evaluation Center, Massachusetts General Hospital, 50 Staniford St—9th Floor, Boston, MA 02114, USA (e-mail: mbarry@partners.org).

The first 10% of the full text of this article appears below.

In this issue of the Journal, Draisma et al. (1) thoughtfully and carefully estimate the proportion of prostate cancers overdiagnosed in the United States from 1985 through 2000, the early prostate-specific antigen (PSA) era in the United States. They also examine the lead time of PSA screening in that era, using several different definitions of lead time. They use three different independently developed models to estimate these parameters, calibrating each of the models to the observed incidence of prostate cancer in the United States over this time interval. They estimate an overdiagnosis probability, which is defined as the percentage of prostate cancers diagnosed by screening that would not have been diagnosed before death, from 23% to 42%, depending on the model. The estimated lead time for those prostate cancers . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?

Related Articles in JNCI

IN THIS ISSUE
J Natl Cancer Inst 2009 101: 361. [Extract] [Full Text] [PDF]

Study Methods Influence Estimates of Lead Time and Overdiagnosis in Prostate Cancer
J Natl Cancer Inst 2009 101: 361. [Extract] [Full Text] [PDF]